{
    "clinical_study": {
        "@rank": "114436", 
        "acronym": "ORTHO-2", 
        "arm_group": {
            "arm_group_label": "Cultured autologous Mesenchymal Cells", 
            "arm_group_type": "Experimental", 
            "description": "Cultured Mesenchymal Cells from bone marrow isolation, expanded under GMP protocol in associated facilities and introduced at the end of the appropriate forage up to the femoral head under fluoroscopic control.\n20x106 cells per cc in a single administration of 7cc"
        }, 
        "brief_summary": {
            "textblock": "The purpose is to assess the safety and feasibility  of cellular therapy derived from bone\n      marrow, to help bone healing in patients with avascular necrosis of the hip."
        }, 
        "brief_title": "Evaluation of Mesenchymal Stem Cells to Treat Avascular Necrosis of the Hip", 
        "completion_date": {
            "#text": "February 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Avascular Necrosis of the Femoral Head", 
        "condition_browse": {
            "mesh_term": [
                "Necrosis", 
                "Osteonecrosis", 
                "Femur Head Necrosis"
            ]
        }, 
        "detailed_description": {
            "textblock": "To assess the safety and feasibility of an in situ single injection of a high dose of\n      autologous bone marrow-derived, in vitro expanded Mesenchymal stem cells, and its\n      contribution to the resolution of the early stages of avascular osteonecrosis of the femoral\n      head."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Age 18 to 65, both sexes\n\n          -  Early avascular necrosis of the fem oral head (MRI diagnosis): Ficat and Arlet 0, 1,\n             or 2 (Steinberg stages 0, I, IIA, IIB, or IIC)\n\n          -  Sym ptom atic osteonecrosis with less than 6 months of evolution\n\n          -  Able to provide informed consent, and signed informed consent\n\n          -  Medical health care coverage\n\n        Exclusion Criteria:\n\n          -  Pregnancy, breast feeding women and women who are of childbearing age and not\n             practicing adequate birth control.\n\n          -  Participation in another therapeutic trial in the previous 3 m onths\n\n          -  Stages 3 or m ore (Ficat and Arlet) or III or m ore (Steinberg) of severe fem oral\n             head osteonecrosis,primarily based on diagnosis by im aging (X-Rays, MRI).\n\n          -  Flattening or collapse of the fem oral head (Steinberg stage IV) or articular\n             cartilage collapse at the time of core decompression surgery.\n\n          -  Septic arthritis.\n\n          -  Stress fracture.\n\n          -  Non-osteonecrosis metabolic bone diseases (particularly Paget's disease of bone,\n             osteogenesis imperfecta, primary hyperparathyroidism , fibrous dysplasia monostotic,\n             polyostotic McCune-Albright syndrome] and osteopetrosis).\n\n          -  Any active bisphosphonate treatment or any history of intravenous (IV) treatment.\n\n          -  History of prior or concurrent diagnosis of HIV-, Hepatitis-B- or\n             Hepatitis-C-infection\n\n          -  Active hepatitis B or hepatitis C infection at the time of screening.\n\n          -  Known allergies to products involved in the production process of MSC.\n\n          -  History of neoplasia or current neoplasia in any organ.\n\n          -  Corticoid or immunosuppressive therapy more than one week in the two months prior to\n             study inclusion\n\n          -  Patients who will require continuous, systemic, high dose corticosteroid therapy\n             (more than 7.5 m g/day) within 6 months after surgery.\n\n          -  Patients who are in active treatment for cancer or blood dyscrasia, or have received\n             chemotherapy, radiotherapy or immunotherapy in the past 2 years.\n\n          -  History of regular alcohol consumption exceeding 2 drinks/day  within 6 months of\n             screening and/or history of illicit drug use.\n\n          -  Serum AST (SGO T)/ALT (SGPT) > 2.5 X (institutional standard range).\n\n          -  MRI-incompatible internal devices (pacemakers, aneurysm clips, etc).\n\n          -  Body mass index (BMI) of 40 kg/m \u00b2 or greater.\n\n          -  Patients unable to tolerate general anesthesia defined as an American Society of\n             Anesthesiologists (ASA) criteria of > 2.\n\n          -  Insulin dependent diabetes\n\n          -  Patients with poorly controlled diabetes mellitus (HbA1C > 8%), or with peripheral\n             neuropathy, or known concomitant vascular problems.\n\n          -  Patients receiving treatment with hematopoietic growth factors or anti-vasculogenesis\n             or antiangiogenesis treatment.\n\n          -  Traumatic osteonecrosis.\n\n          -  Adult in the care of a guardian (Subject legally protected)\n\n          -  Im possibility to meet at the appointments for the clinical follow up."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 12, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02065167", 
            "org_study_id": "ORTHO -2", 
            "secondary_id": "2012-002010-39"
        }, 
        "intervention": {
            "arm_group_label": "Cultured autologous Mesenchymal Cells", 
            "description": "Cultured Mesenchymal Cells from bone marrow isolation, expanded under GMP protocol in associated facilities and introduced at the end of the appropriate forage up to the femoral head under fluoroscopic control.", 
            "intervention_name": "Cultured autologous Mesenchymal Cells", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "avascular necrosis of femoral head", 
            "cell therapy", 
            "Mesenchymal stem cells"
        ], 
        "lastchanged_date": "February 14, 2014", 
        "link": {
            "description": "web page of the REBORNE consortium", 
            "url": "http://www.reborne.org"
        }, 
        "location": [
            {
                "contact": {
                    "email": "philippe.hernigou@wanadoo.fr", 
                    "last_name": "Philippe Hernigou, Dr"
                }, 
                "facility": {
                    "address": {
                        "city": "Cr\u00e9teil", 
                        "country": "France", 
                        "zip": "94000"
                    }, 
                    "name": "Department of Orthopaedic Surgery, H\u00f4pital Henri Mondor"
                }, 
                "investigator": {
                    "last_name": "Philippe Hernigou, Dr", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "rosset@med.univ-tours.fr", 
                    "last_name": "Philippe Rosset, Dr"
                }, 
                "facility": {
                    "address": {
                        "city": "Tours", 
                        "country": "France", 
                        "zip": "37044"
                    }, 
                    "name": "Department of Orthopaedic Surgery, CHU Tours"
                }, 
                "investigator": {
                    "last_name": "Philippe Rosset, Dr", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "michaela.doering@med.uni-tuebingen.de", 
                    "last_name": "Michaela Doering, Dr"
                }, 
                "facility": {
                    "address": {
                        "city": "T\u00fcbingen", 
                        "country": "Germany", 
                        "zip": "72076"
                    }, 
                    "name": "University Children's Hospital"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "florian.gebhard@uniklinik-ulm.de", 
                    "last_name": "Florian Gebhard, Prof"
                }, 
                "facility": {
                    "address": {
                        "city": "Ulm", 
                        "country": "Germany", 
                        "zip": "8907581"
                    }, 
                    "name": "Department of Orthopaedic Trauma, University of Ulm"
                }, 
                "investigator": {
                    "last_name": "Florian Gebhard, Prof", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "nicola.baldini@ior.it", 
                    "last_name": "Nicola Baldini, Prof"
                }, 
                "facility": {
                    "address": {
                        "city": "Bologna", 
                        "country": "Italy", 
                        "zip": "40136"
                    }, 
                    "name": "Istituto Ortopedico Rizzoli"
                }, 
                "investigator": {
                    "last_name": "Nicola Baldini, Prof", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "enrique.gomezbarrena@uam.es", 
                    "last_name": "Enrique Gomez-Barrena, Prof"
                }, 
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28046"
                    }, 
                    "name": "Servicio de Cirug\u00eda Ortop\u00e9dica y Traumatolog\u00eda \"A\", Hospital La Paz"
                }, 
                "investigator": {
                    "last_name": "Enrique Gomez-Barrena, Prof", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "France", 
                "Germany", 
                "Italy", 
                "Spain"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "Evaluation of Safety and Feasibility of Bone Marrow Derived Autologous MSCs to Enhance Bone Healing in Patients With Avascular Necrosis of the Femoral Head", 
        "overall_contact": {
            "email": "enrique.gomezbarrena@uam.es", 
            "last_name": "Enrique Gomez-Barrena, Prof"
        }, 
        "overall_official": {
            "affiliation": "Universidad Autonoma de Madrid, Hospital la Paz", 
            "last_name": "Enrique Gomez-Barrena, Prof", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios", 
                "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
                "Germany: Paul-Ehrlich-Institut", 
                "Italy: The Italian Medicines Agency"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "February 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Includes early local complication rate plus global complication rate, as the percentage of patients with local or general complications at 52 weeks.", 
            "measure": "Complication rate", 
            "safety_issue": "Yes", 
            "time_frame": "12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02065167"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Universidad Autonoma de Madrid", 
            "investigator_full_name": "Prof Enrique Gomez-Barrena", 
            "investigator_title": "Full Professor and Chair of orthopaedic surgery", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Local and general complication rate", 
                "measure": "complication rate", 
                "safety_issue": "Yes", 
                "time_frame": "6,12,24,104 weeks"
            }, 
            {
                "measure": "Progression of disease to the next stage", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Amount of necrotic bone in the femoral head in MRI", 
                "safety_issue": "No", 
                "time_frame": "12 weeks and 52 weeks"
            }, 
            {
                "measure": "Pain", 
                "safety_issue": "No", 
                "time_frame": "6,12,24,52,104 weeks"
            }, 
            {
                "measure": "serum levels of bone turnover markers", 
                "safety_issue": "No", 
                "time_frame": "12 and 24 weeks"
            }
        ], 
        "source": "Universidad Autonoma de Madrid", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Universidad Autonoma de Madrid", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}